Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06696742
PHASE2

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

Sponsor: The First Affiliated Hospital with Nanjing Medical University

View on ClinicalTrials.gov

Summary

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

Official title: Study on the Efficacy of Neoadjuvant or Adjuvant Therapy Based on PD1 Inhibitors Combined With Clostridium Butyricum Supplementation for Urothelial Carcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-02-01

Completion Date

2029-02-01

Last Updated

2024-11-20

Healthy Volunteers

No

Interventions

DRUG

Clostridium Butyricum Tablets

Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets

DRUG

Cisplatin

Gemcitabine and Cisplatin

Locations (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China